Cannabidiol

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

Retrieved on: 
Tuesday, October 10, 2023
Cardiovascular disease, Syndrome, TSX, Cannabidiol, BNP, Hypertension, Obesity, Tibia, Death, Inflammation, Development, Risk, Adipose tissue, Human, Diabetes, VAT, Patient, SAT, Therapy, Heart failure, Lipid metabolism, CRDL, Fibrosis, Skin, Research, Pharmaceutical industry, Heart failure with preserved ejection fraction

Toronto, Ontario--(Newsfile Corp. - October 10, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces positive study results from one of its international collaborating research centers demonstrating that subcutaneously administered cannabidiol, the active pharmaceutical ingredient in Cardiol's novel CRD-38 subcutaneous ("SUBQ") formulation, slowed increases in body weight and heart weight, and prevented increases in key cardiac inflammatory and remodelling markers in a model of heart failure with preserved ejection fraction ("HFpEF").

Key Points: 
  • The study was presented by researchers from Tecnológico de Monterrey, Mexico ("TecSalud") at the Heart Failure Society of America Annual Scientific Meeting 2023 ("HFSA2023").
  • TecSalud is one of the Company's international collaborating research centers working towards the common goal of developing products to advance the treatment of heart diseases.
  • The results presented at the HFSA over the weekend demonstrated multiple cardioprotective effects of SUBQ administered cannabidiol and provide additional evidence in support of the development of CRD-38, our novel SUBQ formulation of cannabidiol intended for the treatment of heart failure.
  • The poster entitled "Cannabidiol As A Potential Treatment For Heart Failure With Preserved Ejection Fraction" was presented on October 7th within the "ePoster Viewing Session III" of HFSA2023.

North America Leads the CBD Boom as the Largest Market, Fueled by Favorable Regulatory Changes and Investments in Medicinal CBD Research - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 12, 2023
Cannabis, Natural Resources, Cream, Market, Yoga, Investment, Health, COVID-19, Timeline of cannabis laws in the United States, THC, Pharmacy, Anxiety, Lead, Research, Distribution, Crohn's disease, Epilepsy, Pain management, Cancer, Nausea, Education, DSM-IV codes, Seizure, Oil, Marketing, Dystonia, Depression, Chronic pain, Alzheimer's disease, Skin, Spasm, Social media, Arthritis, Conditional sentence, Argyreia nervosa, Parkinson's disease, Pharmaceutical industry, Dietary supplement, Drug, Cannabidiol, Capsule, Tablet, CBD

The global CBD (Cannabidiol) market is on a trajectory of substantial growth, with a projected value of US$6.17 billion by 2023.

Key Points: 
  • The global CBD (Cannabidiol) market is on a trajectory of substantial growth, with a projected value of US$6.17 billion by 2023.
  • The versatility of CBD is evident in its various forms, such as pills, patches, oils, extracts, vape pens, and topical skin treatments.
  • The global CBD market encompasses four regions: North America, Europe, Asia Pacific, and the Rest of the World.
  • Additionally, the presence of major market players further fuels growth, alongside increasing investments and favorable government initiatives.

SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder

Retrieved on: 
Friday, September 29, 2023
DSM-IV codes, Central nervous system, Social, Autism spectrum, Clinical trial, Quality of life, Clinical Global Impression, Disorder, TEL, PEA, Patient safety, ASD, Deviance (sociology), Neurology, Cannabidiol, Safety, Pharmaceutical industry, CBD

Designed as a randomized, double-blind, placebo-controlled trial with a cross-over study, the trial will span 20 weeks and involve 60 children between 5-18 years old.

Key Points: 
  • Designed as a randomized, double-blind, placebo-controlled trial with a cross-over study, the trial will span 20 weeks and involve 60 children between 5-18 years old.
  • Partnering with the National Autism Research Center, Israel's foremost authority on autism research, underscores our unwavering commitment to scientific rigor and patient safety.
  • The trial was designed in collaboration with the National Autism Research Center, Israel's leading institution for autism research.
  • The term "spectrum" in Autism Spectrum Disorder encapsulates the wide array of symptoms and severity levels associated with this complex condition.

Vantage Hemp Co. Concludes Audit with Australia’s Therapeutic Goods Administration

Retrieved on: 
Thursday, September 21, 2023
GMP, Regulation of therapeutic goods, Good manufacturing practice, Vantage, Therapeutic Goods Administration, ICH, Government, PIC/S, Documentation, Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme, WHO, TGA, FDA, Cannabidiol, Medical device, Audit, CBD

Greeley, Colorado, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Vantage Hemp Co. (“Vantage” or the “Company”) announces the completion of a rigorous four-day audit conducted by Australia's Therapeutic Goods Administration (TGA), the country’s government authority responsible for evaluating, assessing, and monitoring products that are defined as therapeutic goods.

Key Points: 
  • Greeley, Colorado, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Vantage Hemp Co. (“Vantage” or the “Company”) announces the completion of a rigorous four-day audit conducted by Australia's Therapeutic Goods Administration (TGA), the country’s government authority responsible for evaluating, assessing, and monitoring products that are defined as therapeutic goods.
  • The audit, which took place from August 22-25, 2023, was a comprehensive assessment of Vantage’s operations, focusing on compliance with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and the Therapeutic Goods Order No.
  • The process leading up to the audit spanned several months and included steps such as applying for exporter status, submitting documentation, and gaining approval for inspection.
  • The TGA auditor conducted a thorough examination of the Company's facilities, processes, and quality management systems.

Global Cannabis Beverages Strategic Analysis Report 2023: Market to Reach $3.9 Billion by 2030 - Alcoholic Beverage Companies Seek Role in the Market - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 20, 2023
Alternative Medicine, Cannabis, Retail, Health, Natural Resources, Pharmaceutical, Food, Beverage, Real, Energy drink, Transformation, Alcoholism, COVID-19, Cardiovascular disease, Stroke, Developed country, Development, Disruption, Risk, Growth, THC, Drug, Video game, Cannabidiol, CBD

The "Cannabis Beverages: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cannabis Beverages: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Cannabis Beverages estimated at US$1 Billion in the year 2022, is projected to reach a revised size of US$3.9 Billion by 2030, growing at a CAGR of 17.7% over the analysis period 2022-2030.
  • The global market for cannabis beverages is experiencing significant growth, with sales expected to increase steadily from 2022 through 2030.
  • The market encompasses a range of products, including non-alcoholic and alcoholic cannabis beverages, as well as those containing Tetrahydrocannabinol (THC) and Cannabidiol (CBD).

Three New Articles in the Special Issue "Single-Cell and Spatially Resolved Omics - I" of Journal of Pharmaceutical Analysis Articles Describe How Single-Cell and Spatially Resolved Omics Can Identify Novel Therapeutic Targets

Retrieved on: 
Tuesday, September 19, 2023
Communication, Therapy, Macrophage, ATAC, AEW, JPA, Ageing, Cannabinoid, Atopic dermatitis, Medicine, Research, Gene expression, RNA, Immunology, Immunotherapy, Psoriasis, B cell, Incidence, Neuroscience, Patient, Cancer, Keratinocyte, Immune system, Biology, Mouse, Dick's Picks Volume 13, Microglia, CSF, APP, AD, Tumor microenvironment, Alzheimer's disease, Cannabidiol, Vaccine, CBD

The latest Special Issue of JPA features three articles showcasing tremendous advances and potential of these approaches for uncovering novel biological insights and informing the development of novel therapeutics.

Key Points: 
  • The latest Special Issue of JPA features three articles showcasing tremendous advances and potential of these approaches for uncovering novel biological insights and informing the development of novel therapeutics.
  • The first study investigated the potential of cannabidiol (CBD), a compound found in the cannabis plant, for the treatment of colorectal tumors.
  • The article was available online in April 2023 and published in Volume 13, Issue 7 of the journal in July 2023 .
  • These studies offer hope that further research using single-cell and spatially resolved omics would ultimately lead to treatments for challenging diseases.

Cannabis Testing Market to grow by USD 1.50 billion from 2022-2027 | North America to account for 46% of market growth - Technavio

Retrieved on: 
Monday, September 18, 2023
Segment, Information management, USD, ROW, LC-MS, Cannabis, Growth, Research, Cannabidiol, Software, Drug, Retail, Geography

The US and Canada are the key markets for the cannabis testing market in North America.

Key Points: 
  • The US and Canada are the key markets for the cannabis testing market in North America.
  • Furthermore, the market growth in this region will be faster than the growth of the market in other regions.
  • Factors such as the growing adoption of information management solutions will facilitate the cannabis testing market growth in North America.
  • Growth of the cannabis testing market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of cannabis testing market vendors.

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium

Retrieved on: 
Thursday, September 14, 2023
Honey, SSBP, Clinician Administered PTSD Scale, University, MBBS, Medical school, DM, FRACP, Associate professor, Efficacy, Adolescence, Maharashtra University of Health Sciences, University of Queensland, INSPIRE, Syndrome, The Society, Pharmaceutical industry, Vaccine, Cannabidiol

Helen (Honey) Heussler, MBBS FRACP, DM, Associate Professor, Faculty of Medicine, Child Health Research Centre, University of Queensland, Australia, will present data from the open-label Phase 2 INSPIRE trial.

Key Points: 
  • Helen (Honey) Heussler, MBBS FRACP, DM, Associate Professor, Faculty of Medicine, Child Health Research Centre, University of Queensland, Australia, will present data from the open-label Phase 2 INSPIRE trial.
  • A copy of the presentation will be available on the Zynerba corporate website at www.zynerba.com/publications .
  • Zygel was shown to be generally well tolerated, and the safety profile was consistent with previously released data from other Zygel clinical trials.
  • Three patients reported treatment related adverse events which were all mild in severity and application site related.

Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th

Retrieved on: 
Wednesday, September 6, 2023
Cognition, The central science, Depression, Anxiety, Cancer, Absorption, Solubility, Social, Pain, CBD, Drug development, Pharmaceutical industry, Cannabidiol

SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Myles Osborn, Medicinal Chemist at Artelo Biosciences, will be presenting at the 6th Cannabinoid-Derived Drug Development Summit being held September 11-13, 2023 at the Hilton Boston Back Bay hotel in Boston, MA.

Key Points: 
  • SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Myles Osborn, Medicinal Chemist at Artelo Biosciences, will be presenting at the 6th Cannabinoid-Derived Drug Development Summit being held September 11-13, 2023 at the Hilton Boston Back Bay hotel in Boston, MA.
  • Mr. Osborn’s presentation, titled “Improving Cannabidiol for Oral Solid Dosage Form Drug Products,” is scheduled for 1:45 p.m. Eastern Time on Tuesday, September 12, 2023.
  • During the presentation, Mr. Osborn will discuss how co-crystallization assists with improving the pharmaceutical properties of a drug, including solubility, dissolution and absorption as well as present data on ART12.11, Artelo’s patented CBD cocrystal, in preclinical chronic stress models measuring anxiety, depression, sociability, and cognition.

Aphios Awarded an NIH Grant For a Combination Therapeutic for Chronic Opioid Use Disorder Relapse

Retrieved on: 
Wednesday, September 6, 2023
Science, Research, General Health, Health, Mental Health, Engineering, Manufacturing, Other Health, Nanoparticle, Therapy, Service, Narcotic, Naltrexone, NIH, Risk, Cannabidiol, Buprenorphine, SBIR, Pharmaceutical industry, CBD

Aphios announced today that it was awarded an NIH grant to develop a combination therapeutic for chronic opioid use disorder relapse.

Key Points: 
  • Aphios announced today that it was awarded an NIH grant to develop a combination therapeutic for chronic opioid use disorder relapse.
  • Aphios was awarded a Phase I Small Business Innovation Research (SBIR) grant to develop a sustained release combination therapeutic for chronic opioid use disorder relapse that includes cannabidiol (CBD) in biodegradable polymer nanospheres.
  • Unlike current treatments, cannabidiol (CBD), a bioactive ingredient of marijuana, is not an opioid and is non-psychoactive.
  • According to Dr. Trevor P. Castor, Aphios’ President and CEO, “CBD encapsulated in nanoparticles will improve therapeutic efficacy for opioid use disorder relapse while reducing side-effects, and increasing adherence and accessibility.